Curative or non-curative: immunotherapy for advanced melanoma
Journal Title
JNCI Cancer Spectrum
Publication Type
Online publication before print
Abstract
Advanced melanoma was historically considered incurable, however a 52% 10-year melanoma-specific survival rate from seminal immunotherapy trials challenges that conclusion 1. There is no literature exploring clinicians' discussion of treatment-intent with patients, or whether this represents cure. We performed a multi-center retrospective cohort analysis to examine treatment-intent, using electronic medical records to identify 278 patients with unresectable or stage IV melanoma consented for immunotherapy from 2019-2023. 32 (12%) were consented for curative-intent treatment (CIT). CIT frequency was not significantly influenced by patient or disease characteristics. Patients consented for CIT received significantly higher rates of combination immunotherapy than patients consented for non-curative-intent treatment (NCIT), 76% (16/21) vs 47% (116/246), p 0.022. Among 267 unresectable patients, CIT rates differed significantly between Victoria and South Australia, 14% (20/142) vs 0.8% (1/125), p < .001. Our data confirms variability of documented treatment-intent in advanced melanoma. Further research is needed to understand how this impacts patients.
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1093/jncics/pkaf041
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-06-02 04:28:18
Last Modified: 2025-06-02 04:28:43

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙